In xenograft and liver metastasis models, the sequential administration of folic acid-modified milk exosomes loaded with c-kit siRNA (FA-mExo-siRNA-c-kit) followed by gefitinib resulted in decreased tumor growth and improved survival rates. This evidence concerns the gene KIT and neoplasm.